NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

Targeting KRAS Mutations in Advanced NSCLC

EP. 1: Evolution of Targeted Therapy in Advanced NSCLC

ByTargeted Oncology

May 27th 2020

EP. 2: Targeted Therapy in NSCLC: Improvements in Molecular Testing

ByTargeted Oncology

May 27th 2020

EP. 3: History of KRAS Testing in Advanced NSCLC

ByTargeted Oncology

May 27th 2020

EP. 4: An Overview of KRAS Tumor Biology

ByTargeted Oncology

May 27th 2020

EP. 5: KRAS Mutation Subtypes in Advanced NSCLC

ByTargeted Oncology

May 27th 2020

EP. 6: Advanced NSCLC: Rationale Behind KRAS Inhibition

ByTargeted Oncology

May 27th 2020

EP. 7: KRAS-Mutant NSCLC: Current Systemic Treatment Options

ByTargeted Oncology

May 27th 2020

EP. 8: Impact of Coalterations on KRAS-Mutant NSCLC

ByTargeted Oncology

May 27th 2020

EP. 9: KRAS G12C Inhibition in Advanced NSCLC: AMG 510

ByTargeted Oncology

May 27th 2020

EP. 10: Practical Considerations for AMG 510 in KRAS-Mutant NSCLC

ByTargeted Oncology

May 27th 2020

EP. 11: KRAS G12C Inhibition in Advanced NSCLC: MRTX849

ByTargeted Oncology

May 27th 2020

EP. 12: KRAS G12C Inhibitors: Acquired Resistance and Combo Strategies

ByTargeted Oncology

May 27th 2020

EP. 13: Future Directions in Managing KRAS-Mutant Advanced NSCLC

ByTargeted Oncology

May 27th 2020

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The Targeted Pulse: FDA Actions and Trial Analyses

Greater Adverse Effect Bother Associated With Early Treatment Discontinuation

Medication Burden Linked With Acute Care Use in ARSI-Treated Prostate Cancer

Exploring the IO Interface: Bridging Knowledge Gaps in Immunotoxicity Management

© 2025 MJH Life Sciences^®

All rights reserved.